ODT in BE study [Design Issues]

posted by Farmacevt – North Macedonia, 2022-01-18 17:01 (379 d 03:10 ago) – Posting: # 22732
Views: 957


I would appreciate if you can share your opinion regarding this particular case:

IF you develop generic orodispersible tablet (ODT) and the reference formulation is immediate release tablet (obviously it can be administrate only with water) is it enough to perform two way cross-over study where the ODT will be administrated without water and the reference tbl. with water, or 3 arm study (ODT administrated in both ways with and without water and the reference with water) should be performed?

Thank you

Complete thread:

UA Flag
 Admin contact
22,478 posts in 4,708 threads, 1,603 registered users;
20 visitors (0 registered, 20 guests [including 4 identified bots]).
Forum time: 20:12 CET (Europe/Vienna)

I think it is much more interesting to live with uncertainty
than to live with answers that might be wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz